McDougle et al. aggression is a common clinical manifestation of autistic disorder (autism) and conduct disorder. Treatment of Aggression in Children and Adolescents With Autism and Conduct Disorder Christopher J. McDougle, M.D.; Kimberly A. Stigler, M.D.; and David J. Posey, M.D. The optimal clinical management of aggression in children and adolescents involves both behavioral and pharmacologic intervention strategies. This article reviews medication treatments for youngsters with autistic disorder and conduct disorder, conditions for which the pharmacologic management of aggression is often necessary. Efficacy results and associated adverse effects from selected clinical trials of most classes of psychotropic medications are discussed. While preliminary progress has been made in the development of medication treatments for these serious disorders of youth, additional controlled research and longitudinal studies are needed to better understand the efficacy and tolerability of currently available compounds within each diagnostic group.

(A J Clin Psychiatry 2003;64[suppl 4]:16–25)

From the Department of Psychiatry, Indiana University School of Medicine, Indianapolis.

This work was supported in part by a Young Investigator Award from the National Alliance for Research in Schizophrenia and Depression (Dr. Posey), a Daniel X. Freedman Psychiatric Research Fellowship Award (Dr. Posey), Department of Housing and Urban Development grant B-01-SP-IN-0200 (Dr. McDougle), and a Research Unit on Pediatric Psychopharmacology Contract (NO1MH70001) from the National Institute of Mental Health, Rockville, Md., to Indiana University (Drs. McDougle and Posey).

Corresponding author and reprints: Christopher J. McDougle, M.D., Department of Psychiatry, Indiana University School of Medicine, 1111 W. 10th St., KI 2nd Floor, Indianapolis, IN 46202-4800.

A ggression is a common clinical manifestation of autistic disorder (autism) and conduct disorder. Although behavioral therapy can be an effective treatment modality for both conditions, pharmacotherapy is frequently indicated. This article reviews relevant studies on the pharmacologic treatment of aggression in children and adolescents with these disorders.

AUTISTIC DISORDER

Autism and other pervasive developmental disorders (PDDs) are characterized by severe and pervasive impairment in reciprocal social interaction, communication, and behavior. PDDs are typically evident in the first few years of life and are frequently associated with mental retardation. Treatment is multimodal and largely based on educational and behavioral interventions. While speech therapy is essential for optimizing outcome, physical and occupational therapy are also often needed.

Despite the available nonpharmacologic interventions, many individuals with autism remain significantly impaired. Under these circumstances, pharmacologic treatment is often necessary. Medication can be useful for reducing interfering symptoms, thus allowing other treatment interventions to proceed more effectively.

A number of behavioral symptoms, including hyperactivity; inattention; impulsivity; aggression toward self, others, or property; and interfering repetitive thoughts and behavior, are often present in patients with PDDs. Different classes of psychotropic agents have been found to be helpful for particular domains of symptom impairment. The reader is referred to a recent, comprehensive review of drug treatment for this broad range of symptoms commonly observed in patients with autism and other PDDs. Here, proceeding by class of drug, we describe efficacy and safety results from selected trials in autistic subjects for whom aggression was a primary target of pharmacotherapy (Table 1).

Typical Antipsychotics

Typical antipsychotics were among the first medications to be assessed systematically in autistic children. Indeed, they have often been prescribed to treat severe aggression in individuals with developmental disabilities in general. Most of the available typical antipsychotics, including many low-potency agents, were studied in heterogeneous samples of children that included autistic subjects. While these agents were often found to be helpful for reducing symptoms of aggression, their adverse effects...
tended to outweigh any clinical benefit. The lower potency antipsychotics tended to cause sedation and cognitive impairment, particularly at higher doses, which interfered with educational and other programming attempts. Regarding the high-potency antipsychotics, Campbell and coworkers\textsuperscript{3–5} conducted several well-designed controlled studies of haloperidol in autistic children. In doses of 1 to 2 mg/day, haloperidol was found to be more efficacious than placebo for affective lability, anger, and temper outbursts. However, acute dystonic reactions, along with withdrawal and tardive dyskinesias, were not infrequent.\textsuperscript{6,7}

**Atypical Antipsychotics**

The atypical antipsychotics may have a reduced propensity toward motor side effects, including tardive dyskinesia secondary to their potent antagonism at both dopamine (DA) and serotonin (5-hydroxytryptamine, 5-HT) receptors. Clinically, they are among the most effective drugs for reducing aggression in individuals with autism.

**Clozapine.** Two case reports found clozapine, in doses of 200 to 450 mg/day, effective for reducing aggression in children and adolescents with autism.\textsuperscript{8,9} The limited number of reports of clozapine treatment might reflect concern about the risks of seizures and agranulocytosis that are associated with the drug. Additionally, the need for frequent blood draws is not ideal for children with autism.

**Risperidone.** Among the available atypical antipsychotics, risperidone has received the most attention as a potential treatment for aggression associated with autism. In a double-blind, placebo-controlled trial of risperidone (mean ± SD dose = 2.9 ± 1.4 mg/day) involving 31 adults with autism, a significant reduction occurred in aggression toward self, others, and property.\textsuperscript{10} Mild transient sedation was the most common adverse effect in this study. The National Institute of Mental Health–sponsored Research Units on Pediatric Psychopharmacology (RUPP) Autism Network recently completed the largest drug study to date in children with autism (N = 101).\textsuperscript{11} In this 8-week double-blind, placebo-controlled, parallel-group study, risperidone (mean dose = 1.8 ± 0.7 mg/day) was found to be significantly more efficacious than placebo for the treatment of aggression and irritability (Figure 1). Weight gain, increased appetite, sedation, tremor, and hypersalivation were more common in the risperidone- versus the placebo-treated group.

**Olanzapine.** Case reports, an open-label case series,\textsuperscript{12} and a prospective, open-label comparison with haloperidol\textsuperscript{13} have described reductions in aggression in patients with autism and other PDDs treated with olanzapine. In a recently published study using a parallel-group design, 12

---

### Table 1. Selected Double-Blind Placebo-Controlled Studies Targeting Aggression in Autistic Disorder

<table>
<thead>
<tr>
<th>Medication</th>
<th>Symptoms Improved</th>
<th>Significant Adverse Effects</th>
<th>Comments</th>
<th>Reference No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haloperidol</td>
<td>Affective lability, anger, temper outbursts</td>
<td>Acute dystonic reactions, withdrawal and tardive dyskinesias</td>
<td>No controlled studies in adults</td>
<td>3–7</td>
</tr>
<tr>
<td>Risperidone</td>
<td>Aggression, irritability</td>
<td>Mild transient sedation</td>
<td>Conducted in adults</td>
<td>10</td>
</tr>
<tr>
<td>Risperidone</td>
<td>Aggression, irritability</td>
<td>Weight gain, increased appetite, sedation, tremor, hypersalivation</td>
<td>Largest controlled study to date in children with autism</td>
<td>11</td>
</tr>
<tr>
<td>Clomipramine</td>
<td>Aggression, self-injury</td>
<td>QTc prolongation, tachycardia, seizure</td>
<td>Conducted in children and young adults</td>
<td>23</td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>Aggression, repetitive phenomena</td>
<td>Nausea, sedation</td>
<td>No controlled pediatric data; unpublished pediatric data unfavorable</td>
<td>25</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>No better than placebo</td>
<td>Insomnia, hyperactivity</td>
<td>Study did not specifically focus on aggression</td>
<td>35</td>
</tr>
<tr>
<td>Methylphenidate</td>
<td>Hyperactivity, irritability</td>
<td>Minimal</td>
<td>Modest improvement in hyperactivity; 2 of 10 required addition of haloperidol to manage aggression</td>
<td>37</td>
</tr>
<tr>
<td>Clonidine</td>
<td>Hyperactivity, irritability, oppositional behavior, aggression, self-injury</td>
<td>Hypotension, sedation, decreased activity</td>
<td>Small number of subjects</td>
<td>38</td>
</tr>
</tbody>
</table>

---

**Figure 1. Mean Score for Irritability in Risperidone- Vs. Placebo-Treated Children With Autism**

*Reprinted from Research Units on Pediatric Psychopharmacology Autism Network,\textsuperscript{11} with permission. Higher Scores on the Irritability subscale of the Aberrant Behavior Checklist indicate greater irritability.
children with autism were randomly assigned to 6 weeks of open-label treatment with olanzapine or haloperidol. Mean final daily dosages were 7.9 ± 2.5 mg for olanzapine and 1.4 ± 0.7 mg for haloperidol. Five of 6 subjects in the olanzapine group were rated as responders compared with 3 of 6 subjects treated with haloperidol. Weight gain from baseline to the end of the trial was significantly higher in the olanzapine group (mean = 9.0 ± 3.5 lb; range, 5.9 to 15.8 lb [4.1 ± 1.6 kg; range, 2.6 to 7.1 kg]) than in the haloperidol group (mean = 3.2 ± 4.9 lb; range, –5.5 to +8.8 lb [1.4 ± 2.2 kg; range, –2.5 to +3.9 kg]). One subject given haloperidol demonstrated mild rigidity, whereas no subject treated with olanzapine showed motor side effects.13

**Quetiapine.** There has been only 1 report describing quetiapine treatment in autism.14 Of the 6 subjects who participated in the 16-week open-label trial, which was targeted toward aggression and irritability, only 1 showed sustained benefit. Side effects included sedation, increased appetite, weight gain (range, 2–18 lb [0.9–8.1 kg]), behavioral activation, and a possible seizure in 1 subject.

**Ziprasidone.** Ziprasidone is the fifth atypical antipsychotic to be marketed in the United States.15 In controlled studies to date involving adults with schizophrenia16,17 and children and adolescents with Tourette’s disorder,18 ziprasidone has not been associated with significant weight gain or other serious adverse effects. Our group recently found 6 of 12 youths with autism responsive to open-label ziprasidone (mean dose = 59.2 ± 34.8 mg/day).19 The target symptoms included aggression, agitation, and irritability. Among the 8 patients who experienced side effects, transient sedation was most common. One patient with a history of tardive dyskinesia involving his hands developed an oral dyskinesia that resolved upon drug discontinuation. Otherwise, no serious adverse effects occurred, including cardiac side effects. The mean change in weight for the entire group was –5.8 ± 12.5 lb (–2.6 ± ±5.6 kg) (range, –35 to +6 lb [–15.8 ± +2.7 kg]). The weight loss was likely due to the gradual decrease and discontinuation of a concurrently administered atypical antipsychotic agent.

**Serotonin Reuptake Inhibitors**

Many lines of evidence point to abnormalities in 5-HT function in autism.20 Serotonin reuptake inhibitors (SRIs) were initially hypothesized to have efficacy based on the presumed 5-HT dysfunction and because of some of the similarities between obsessive-compulsive disorder and the repetitive phenomena seen in autism.21 In addition, serotonergic drugs have been shown to have antiaggressive properties.22

**Clomipramine.** Clomipramine (mean dose = 152 ± 56 mg/day), a tricyclic antidepressant, was found to be superior to placebo and desipramine for the treatment of several symptoms, including anger/uncooperativeness and self-injury, in children and young adults with autism.23 In a large, open-label trial in 35 adults with PDDs, clomipramine (mean dose = 139 ± 50 mg/day) was effective for reducing aggression, among other symptoms.24 Despite its probable effects on treating aggression in autism, clomipramine is not frequently prescribed for this symptom cluster due to concerns about tolerability and the availability of the safer selective SRIs (SSRIs).

**Fluvoxamine.** To date, there is only 1 published placebo-controlled trial of an SSRI in autism. McDougle and colleagues25 compared fluvoxamine (mean dose = 276.7 ± 41.7 mg/day) and placebo in 30 adults with autism for 12 weeks. Eight of 15 patients in the fluvoxamine group compared with none in the placebo group were categorized as “much improved” or “very much improved” on the Clinical Global Impressions (CGI) scale. Fluvoxamine was significantly more effective than placebo for reducing repetitive phenomena, maladaptive behavior, and aggression. Adverse effects of nausea and sedation were minimal and self-limited.

Results from studies of SSRIs in children and adolescents with autism have not been as encouraging. In a study involving pediatric patients with PDDs, McDougle and colleagues (C.J.M.; J. P. Holmes, R.N., M.S.N.; L. H. Price, M.D.; unpublished data, Sept. 1997) found that fluvoxamine (mean dose = 106.9 mg/day) was efficacious in only 1 of 18 fluvoxamine-treated subjects compared with none of 16 placebo-treated subjects. Fluvoxamine was poorly tolerated and caused increased aggression in 5 subjects. This difference in rates of improvement between children and adults suggests possible developmental differences in drug responsibility and tolerability in autism.

**Other SSRIs.** Case reports and open-label studies suggest that other SSRIs may reduce aggression in some persons with autism. In a retrospective case series of adults with PDDs and comorbid mental retardation, Branford and colleagues26 found that 6 (24%) of 25 patients treated with fluoxetine and 3 (25%) of 12 patients given paroxetine were rated as “much improved” or “very much improved” on the CGI scale in terms of perseverative behaviors, aggression, and self-injury. However, in an open-label study of fluoxetine in 37 children with PDDs (age range, 2.2–7.8 years), aggression was a frequent cause for drug discontinuation.27 McDougle and colleagues28 examined the short-term effectiveness of sertraline in adults with PDDs and found it beneficial in 24 (57%) of 42 subjects, primarily for reducing repetitive and aggressive symptoms. In a 4-month, open-label study of 15 adults with severe and profound mental retardation (7 with PDD), paroxetine at doses of 20 to 50 mg daily was significantly effective for symptoms of aggression at 1 month, but not at 4-month follow-up.29

**Mirtazapine.** Because SSRIs are frequently associated with activating side effects in prepubertal children with autism, other serotonergic drugs that may cause less agitation have recently been studied. Posey and colleagues30 found the serotonergic and noradrenergic antidepressant mirtazapine effective in a treatment-refractory group of subjects...
with PDDs. Mirtazapine (mean dose = 30.3 ± 12.6 mg/day) was helpful in 9 (35%) of 26 subjects for symptoms that included aggression and self-injury. Thus, mirtazapine may represent an option for the treatment of irritability and aggression in autistic children unable to tolerate SSRIs.

**Mood Stabilizers**

Mood stabilizers, namely lithium and the anticonvulsants, have been used to treat aggression in a variety of neuropsychiatric disorders, including autism. Case reports have found lithium effective for maniclike symptoms, aggression, and self-injury.31,32 There has also been 1 case report of lithium augmentation of fluvoxamine in the treatment of an adult with autism.33 Hollander and colleagues34 recently reported results of a retrospective review of divalproex sodium in PDDs. In this study, divalproex sodium (mean dose = 768 mg/day) was associated with improvement in 10 of 14 subjects (age range, 5–40 years). Improvement was seen in affective instability, aggression, and repetitive behavior. Most recently, Belsito and colleagues35 conducted a double-blind, placebo-controlled trial of lamotrigine in 28 children with autism. In this investigation, lamotrigine (mean dose = 5.0 mg/kg/day) was no better than placebo on any of the outcome measures, although this study focused on the overall treatment of autism and not specifically on aggression.

**Psychostimulants**

Psychostimulant treatment is often associated with reductions in aggression in children with attention-deficit/hyperactivity disorder (ADHD).36 However, studies in autism have not found stimulants to be consistently useful for the treatment of aggression. Quintana and colleagues37 administered methylphenidate and placebo in a double-blind, crossover fashion to 10 autistic children (age range, 7–11 years) at doses of 10 or 20 mg twice daily for 2 weeks. Statistically significant improvement was seen in hyperactivity and irritability, and adverse effects were minimal. The authors’ overall impression was that the effects of methylphenidate were modest. After completion of the study, haloperidol was added to the treatment regimen of 2 of the 10 children due to continued symptoms of aggression. Anecdotal reports from physicians in clinical practice often include the onset or exacerbation of irritability, insomnia, and aggression during stimulant treatment of children with autism. A large, controlled study of methylphenidate versus placebo is currently being conducted in children and adolescents with PDDs by the RUPP Autism Network. One goal of this study is to determine if PDD subtype, age, IQ, and dose of drug are associated with response to methylphenidate.

**α2-Adrenergic Agonists**

Clonidine was shown to be effective for reducing hyperactivity and associated symptoms in 2 small, controlled studies of subjects with autism. In a double-blind, placebo-controlled crossover study of clonidine (0.15–0.2 mg/day) in 8 autistic children (age range, 5.0–13.4 years), improvement was seen in hyperactivity, irritability, stereotypes, inattention, and oppositional behavior.38 The most significant treatment effect was a 33% decrease in the irritability subscale of the Aberrant Behavior Checklist, which encompasses tantrums, aggression, and self-injury. Recently, our group reported results of a retrospective review of the effectiveness of guanfacine in children and adolescents with PDDs (D.J.P.; J. I. Puntney, B.A.; T. M. Sasher, B.A.; et al., manuscript submitted, Oct. 2002). Eighty subjects (age range, 3–18 years) were treated with guanfacine (mean dose = 2.6 mg daily) for a mean duration of treatment of nearly 1 year. While guanfacine was modestly effective for tics, hyperactivity, and inattention, it was only effective in 14.5% of the subjects who had significant aggression at baseline.

**β-Adrenergic Agonists**

There have been no published controlled studies of β-blockers in persons with autism. In an uncontrolled study, 19 adults with severe-to-profound mental retardation (1 with autism) were treated with propranolol at doses of 40 to 240 mg daily.39 Eleven patients had symptom improvement in the areas of aggression and self-injury. Hypotension and bradycardia were common dose-related adverse effects. In another uncontrolled study, propranolol (100–360 mg/day) or nadolol (120 mg/day) was effective in decreasing aggression and self-injury in 8 consecutively treated adults with autism.40

**CONDUCT DISORDER**

Conduct disorder is characterized by a repetitive and persistent pattern of disruptive behavior in which the basic rights of others or major age-appropriate societal norms or rules are violated.41 The diverse behaviors observed with this disorder are subdivided into 4 categories: aggression toward people and animals, destruction of property, deceitfulness or theft, and serious violation of rules. Destructive symptoms commonly lead to a significant impairment in functioning across a variety of settings. Conduct disorder is one of the most frequently diagnosed conditions in children and adolescents. Prevalence rates are higher among males than females and vary from less than 1% to more than 10%, according to the population sampled. Children and adolescents with conduct disorder often manifest aggression. Because of its destructive influence, it is this behavior that is frequently brought to the attention of the clinician for evaluation and management. Vitiello and Stoff42 suggest that the efficacy of a range of treatment interventions differs with regard to separate subtypes of aggression. On the basis of a review of the evidence concerning childhood aggression, the available data sup-
port a dichotomy between an “impulsive-affective” and a “controlled-predatory” subtype. According to the authors, this distinction is important in that the controlled-predatory group may be more likely to respond to behavioral therapy, whereas the impulsive-affective group might be expected to be more responsive to pharmacologic and psychosocial interventions intended to decrease hostility, impulsivity, and arousal. Experts in the field concur that the affective subtype of aggression associated with conduct disorder is the feature expected to respond to pharmacologic intervention.42,43 The following sections review the most relevant studies to date on the pharmacologic management of aggression in conduct disorder (Table 2).

### Typical Antipsychotics

The typical antipsychotics are potent dopamine-2 receptor antagonists. Due to their increased propensity for tardive dyskinesia, these compounds are commonly reserved for persons suffering from severe, treatment-resistant symptoms. Their usefulness in decreasing aggression in individuals with conduct disorder has been evaluated in several studies.44,45

Table 2. Selected Double-Blind Placebo-Controlled Studies Targeting Aggression in Conduct Disorder

<table>
<thead>
<tr>
<th>Medication</th>
<th>Symptoms Improved</th>
<th>Significant Adverse Effects</th>
<th>Comments</th>
<th>Reference No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molindone</td>
<td>Aggression, hostility</td>
<td>Dystonia</td>
<td>Molindone as effective as thioridazine</td>
<td>44</td>
</tr>
<tr>
<td>Thioridazine</td>
<td>Aggression, hostility</td>
<td>Sedation, dizziness, headache</td>
<td></td>
<td>44</td>
</tr>
<tr>
<td>Haloperidol</td>
<td>Aggression, explosiveness</td>
<td>Sedation, acute dystonia</td>
<td>Treatment-refractory symptoms</td>
<td>45</td>
</tr>
<tr>
<td>Risperidone</td>
<td>Aggression</td>
<td>Well tolerated</td>
<td></td>
<td>47</td>
</tr>
<tr>
<td>Risperidone</td>
<td>Aggression, destructive behavior</td>
<td>Headache, somnolence, weight gain</td>
<td></td>
<td>48</td>
</tr>
<tr>
<td>Risperidone</td>
<td>Aggression, destructive behavior</td>
<td>Sedation, headache, increased appetite, motor side effects</td>
<td>Motor side effects (13%)</td>
<td>49</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>Aggression, impulsivity</td>
<td>Delayed ejaculation</td>
<td>Decrease in aggression noted at end of 3-week trial</td>
<td>54</td>
</tr>
<tr>
<td>Lithium</td>
<td>Severe aggression, explosiveness</td>
<td>Weight gain</td>
<td>Treatment-refractory symptoms</td>
<td>45, 56</td>
</tr>
<tr>
<td>Lithium</td>
<td>Severe aggression, explosiveness</td>
<td>Weight gain/loss, nausea, vomiting, tremor, headache, polyuria</td>
<td>Treatment-refractory symptoms</td>
<td>56</td>
</tr>
<tr>
<td>Lithium</td>
<td>Aggression</td>
<td>Nausea, vomiting, polyuria</td>
<td>Adverse effects in &gt; 50% of subjects</td>
<td>57</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>Not effective</td>
<td>Well tolerated</td>
<td>Trial duration of only 2 weeks</td>
<td>58</td>
</tr>
<tr>
<td>Divalproex sodium</td>
<td>Aggression, anger</td>
<td>Increased appetite</td>
<td>Study replicated open-label findings</td>
<td>62</td>
</tr>
<tr>
<td>Methylphenidate</td>
<td>Aggression</td>
<td>Dizziness, decreased appetite, headache</td>
<td></td>
<td>63</td>
</tr>
<tr>
<td>Methylphenidate</td>
<td>Aggression toward others and property, antisocial behaviors</td>
<td>Decreased appetite, insomnia</td>
<td>Independent influence of drug on aggression</td>
<td>36</td>
</tr>
<tr>
<td>Methylphenidate</td>
<td>Aggression, symptoms of conduct disorder, impulsivity</td>
<td>Well tolerated</td>
<td></td>
<td>64</td>
</tr>
<tr>
<td>Clonidine</td>
<td>Aggression, symptoms of conduct disorder, impulsivity</td>
<td>Bradycardia</td>
<td></td>
<td>64</td>
</tr>
</tbody>
</table>

Greenhill et al.44 conducted an 8-week, double-blind study of molindone (mean dose = 26.8 mg/day; 1.3 mg/kg/day) and thioridazine (mean dose = 169.9 mg/day; 4.6 mg/kg/day) in 31 hospitalized youngsters (age range, 6–11 years) with conduct disorder. The outcome measures utilized included the Connors Rating Scale, the Inpatient Aggression Scale, and the Children’s Psychiatric Rating Scale (CPRS). Molindone was found to be as effective as thioridazine, as reflected by a significant improvement in all outcome measures. Dystonia and sedation, respectively, were commonly reported adverse effects.

The efficacy and tolerability of haloperidol (mean dose = 2.95 mg/day; range, 1–6 mg/day) and lithium (mean dose = 1166 mg/day; range, 500–2000 mg/day) were investigated in a 4-week, double-blind, placebo-controlled study of 61 hospitalized children (mean age = 8.97 years; age range, 5.2–12.9 years) with conduct disorder.45 Haloperidol and lithium were superior to placebo for decreasing aggression, as measured by the CPRS and CGI scale. Lithium was better tolerated than haloperidol, with weight gain and sedation, respectively, being the most common adverse effect associated with each drug. Acute dystonia was the second most frequent adverse effect associated with haloperidol.

### Atypical Antipsychotics

The atypical antipsychotics, with their profile of potent antagonism at 5-HT and DA receptors, have a lower inci-
dence for tardive dyskinesia. Although research is needed to further understand the role of this class of drugs in individuals with conduct disorder, 4 studies regarding risperidone warrant discussion.46–49

The efficacy and tolerability of risperidone were investigated via a retrospective chart review conducted in 106 patients presenting with various psychiatric disorders.46 Thirteen (12.3%) of the 106 youngsters (mean age = 11.3 years) were diagnosed with conduct disorder. According to CGI-Improvement scale measures, 73% of patients overall were rated as having had a “marked” or “moderate” improvement at the final study assessment. It is important to note that most patients were also taking concomitant medications, including psychostimulants, antidepressants, and clonidine. The authors suggested that risperidone may be useful for managing behavioral disturbances, including aggression, in a variety of psychiatric conditions.

Findling and colleagues published the first double-blind, placebo-controlled study of risperidone (mean dose = 0.028 mg/kg/day; range, 0.02–0.06 mg/kg/day) in 20 children and adolescents (mean age = 9.2 years; range, 6–14 years) with conduct disorder. According to its primary outcome measure, the Rating of Aggression Against People and/or Property (RAAPP) scale, the 10-week study found risperidone superior to placebo for decreasing aggression. Overall, the drug was well tolerated, with none of the risperidone-treated patients developing acute motor side effects. In a set of parallel multicenter studies, the efficacy of risperidone was studied in youngsters diagnosed with subaverage intelligence and comorbid conduct or disruptive behavior disorder.48 In the first 6-week, double-blind, placebo-controlled study, 118 children (age range, 5–12 years) (IQ range, 36–84) with severely disruptive behavior received risperidone (mean dose = 1.16 mg/kg/day; range, 0.02–0.06 mg/kg/day) or placebo. The risperidone group showed significantly greater improvement than did the placebo group on the conduct problem subscale of the Nisonger Child Behavior Rating Form (NCBRF) from week 1 through endpoint (Figure 2). The most common adverse effects reported with risperidone were headache and somnolence. Motor side effects were comparable between risperidone and placebo. A mean weight increase of 4.9 lb (2.2 kg) occurred in the risperidone group.48 The second study involved 110 children (age range, 5–12 years) (mean IQ = 68) treated with risperidone (mean dose = 0.98 mg/day; range, 0.40–3.80 mg/day) or placebo for 6 weeks. Of the 41 subjects with conduct disorder, 31 had a comorbid diagnosis of ADHD. Risperidone resulted in a significant improvement of disruptive behaviors as measured by the NCBRF conduct problem subscale. The authors concluded that risperidone effectively reduced aggression and destructive behavior in this population. Sedation, headache, and increased appetite were among the more commonly reported adverse effects. Motor side effects were reported in 7 (13%) of 53 subjects in the risperidone group.49

Serotonergic Antidepressants

Several studies support an association between 5-HT and aggression.50–52 These promising findings have led to additional investigations regarding the efficacy of serotonergic compounds in patients with conduct disorder. Zubiena and Alessi conducted an open trial of trazodone (mean dose = 241 mg/day; range, 100–800 mg/day), a weak inhibitor of 5-HT reuptake and potent antagonist of 5-HT2A and 5-HT2C receptors, on 22 hospitalized children (mean age = 9 years; age range, 5–12 years) with a disruptive behavior disorder. Thirteen (59%) of 22 children responded to the drug, based on parent interview after discharge from the hospital (mean duration = 8.8 months; range, 3–14 months). Overall, aggression and impulsivity were reported as most often showing improvement. Regarding symptoms more specific to conduct disorder, cruelty to people and animals, destruction of property, and involvement in physical fights were most frequently improved. Adverse effects were judged mild, with the exception of 2 subjects who discontinued the study due to orthostatic hypotension and painful erections, respectively.

Cherek and colleagues investigated the role of the SSRI paroxetine (20 mg/day) in treating aggression and impulsivity in their 3-week, double-blind, placebo-controlled study in 12 adult males with a history of conduct disorder. Experimental sessions were designed to measure aggressive and impulsive responses. When compared with response in the placebo group, decreases in aggressive responses became apparent only by the end of the 3-week trial in the 6 patients receiving paroxetine. The drug was generally well tolerated, with 1 individual report-
ing delayed ejaculation. Another SSRI, citalopram (mean dose = 27 mg/day; range, 20–40 mg/day), was investigated in an open-label fashion in 12 children and adolescents (mean age = 10.2 years; range, 7–15 years) with an impulsive-affected profile of aggression. All 11 completers of this 6-week trial were diagnosed with conduct disorder. Comorbid diagnoses included oppositional defiant disorder (ODD) and ADHD. Citalopram significantly reduced symptoms of aggression as measured by the modified Overt Aggression Scale (OAS), the Child Behavioral Checklist, and the CGI scale. Adverse effects were mild and included sedation, headache, and nightmares.

### Lithium

The monovalent cation lithium, whose mechanism of action is uncertain, has been investigated for the treatment of aggression in patients with conduct disorder. Campbell and colleagues, as previously discussed, found lithium, as well as haloperidol, to be more beneficial than placebo, with lithium being generally well tolerated.

A 6-week, double-blind, placebo-controlled study of lithium (mean dose = 1248 mg/day; range, 600–1800 mg/day) was conducted in 50 hospitalized aggressive youngsters with conduct disorder (mean age = 9.4 years; range, 5.1–12.0 years). The authors reported that lithium was superior to placebo in the management of severe aggression in this population. Common adverse effects included weight gain or loss, nausea, vomiting, tremor, headache, and polyuria.

The effectiveness of lithium for targeting symptoms of aggression was also investigated by Malone et al. in a double-blind, placebo-controlled study of 40 hospitalized children and adolescents (mean age = 12.5 years) with conduct disorder. A 4-week trial of lithium at doses ranging from 900–2100 mg/day (mean dose = 1425 mg/day) was more effective than placebo for reducing aggression as measured by the CGI scale, the Global Clinical Judgment (Consensus) Scale (GCJCS), and the OAS. More than half of the subjects receiving lithium reported nausea, vomiting, and urinary frequency.

In contrast to the above findings, one double-blind, placebo-controlled study failed to support the use of lithium in the management of aggression in subjects with conduct disorder. In this study, 11 (79%) of 14 patients (mean age = 10.2 years; range, 7–15 years) with an impulsive-affected profile of aggression. All 11 completers of this 6-week trial were diagnosed with conduct disorder. Comorbid diagnoses included oppositional defiant disorder (ODD) and ADHD. Citalopram significantly reduced symptoms of aggression as measured by the modified Overt Aggression Scale (OAS), the Child Behavioral Checklist, and the CGI scale. Adverse effects were mild and included sedation, headache, and nightmares.

### Anticonvulsants

Kafantaris and colleagues conducted an open-label study of carbamazepine (mean dose = 630 mg/day; range, 600–800 mg/day) in 10 patients (mean age = 8.27 years; range, 5.25–10.92 years) with conduct disorder. Overall, carbamazepine resulted in a significant improvement in aggression, with all but 1 subject rated as “much improved” or “very much improved” on the CGI scale. Adverse effects were transient and included fatigue, blurred vision, and dizziness.

The efficacy and tolerability of carbamazepine in the treatment of aggression in children within this diagnostic group were also considered by Cueva et al. in a 6-week, double-blind, placebo-controlled study of 22 children (mean age = 8.97 years; range, 5.33–11.70 years). In contrast to the aforementioned open-label study, carbamazepine (mean dose = 683 mg/day; range, 400–800 mg/day) was not superior to placebo in reducing aggression, as measured by the GCJCS, OAS, CGI scale, and CPRS. Rash, transient moderate and marked leukopenia, dizziness, and diplopia were the most common adverse effects.

Donovan and colleagues, in an attempt to replicate open-label findings in support of the efficacy of divalproex sodium in decreasing aggression in subjects with a disruptive behavior disorder (ODD or conduct disorder), investigated the drug in a double-blind, placebo-controlled crossover fashion. Twelve (80%) of 15 patients (mean age = 13.8 years; range, 10–18 years) with a disruptive behavior disorder who completed both 6-week phases of divalproex sodium (mean blood level = 82.2 mg/mL; dose range, 750–1500 mg/day) showed a significant improvement in aggression, as rated by the modified OAS and the Symptom Checklist-90 (SCL-90) anger-hostility items. Divalproex sodium was well tolerated, with increased appetite reported as the only significant adverse effect.

### Psychostimulants

The efficacy of methylphenidate (mean dose = 0.47 mg/kg/day; range, 0.36–0.56 mg/kg/day) on aggression was considered by Kaplan et al. in 9 adolescents (mean age = 14.4 years; range, 13–16 years) with conduct disorder and ADHD. After 3 open trials, a 3-week, double-blind, placebo-controlled crossover design was utilized. The results obtained from the 6 double-blind subjects revealed a significant reduction of aggression as measured by the Adolescent Antisocial Behavior Checklist. Regarding adverse effects, 3 of 9 subjects reported dizziness, appetite loss, and headache.

Klein and colleagues published a 5-week, double-blind, placebo-controlled study of methylphenidate (mean dose = 41.3 mg/kg/day; 1.0 mg/kg/day) in 74 youngsters (mean age = 10.2 years; range, 6–15 years) with conduct disorder. Two thirds of the children also met criteria for ADHD. The authors found that methylphenidate improved key aspects of antisocial adjustment that were independent of the severity of the subjects’ initial ADHD symptoms. In particular, they found an independent influence of the drug...
on aggressive behaviors. Commonly reported adverse effects included decreased appetite and delayed sleep onset.

Another double-blind study compared the efficacy and tolerability of methylphenidate monotherapy (mean dose = 32.5 mg/day), methylphenidate (mean dose = 35.0 mg/day) and clonidine (mean dose = 0.21 mg/day), and clonidine monotherapy (mean dose = 0.17 mg/day) over 3 months in 24 patients (mean age = 9.4 years; range, 6–16 years) diagnosed with ADHD and comorbid ODD or conduct disorder.64 All treatment groups demonstrated significant improvement in symptoms of conduct disorder. Although the 3 treatments were not found to differ significantly from each other over time on most measures, they could not be judged to be equally efficacious due to the small sample size. Overall, the authors suggested that symptoms of disruptive behavior disorders, such as aggression, may be responsive to methylphenidate, clonidine, or the combination, particularly when comorbid with ADHD.

α2-Adrenergic Agonists
The effectiveness of clonidine for symptoms of aggression was investigated by Kemph and colleagues,65 in an open-pilot study of 17 children (mean age = 10.1 years; range, 5–15 years), 15 of whom were diagnosed with conduct disorder. Fifteen (88.2%) of 17 patients demonstrated a significant decrease in aggressive behavior during the administration of clonidine (mean dose = 0.24 mg/day; range, 0.15–0.4 mg/day) over a mean duration of 5.2 months (range, 1–18 months), as measured by the RAAPP scale. Plasma levels of γ-aminobutyric acid increased significantly during treatment and correlated with the reduction of aggression. The most commonly reported adverse effect was sedation at the onset of treatment.

β-Adrenergic Agonists
Although research has demonstrated a therapeutic effect of propranolol in some patients with aggressive behavior,66,67 there is little information available regarding its utility in individuals with conduct disorder. Several open-label studies have suggested that the drug may improve aggression associated with this disorder; however, the subjects often also had considerable central nervous system pathology.66–70

Benzodiazepines
The authors suggest utilizing benzodiazepines with caution due to their potential for abuse and dependence, as well as worsened aggression in this population.71

CONCLUSION
Autism and conduct disorder are representative disorders of childhood and adolescence in which the pharmacologic management of aggression is often necessary. Available research suggests that several classes of medication may effectively target aggression in individuals with these conditions. In patients with autism, potentially helpful medications include the atypical antipsychotics, SSRIs, mirtazapine, mood stabilizers, and α1-adrenergic agonists. Studies completed in patients with conduct disorder support a role for the atypical antipsychotics, SSRIs, mood stabilizers, psychostimulants, and α1-adrenergic agonists. Controlled research and longitudinal studies are needed to better understand the efficacy and tolerability of currently available compounds within each diagnostic group. In addition to well-designed trials, future investigations should attempt to understand the impact of age and other developmental factors on clinical response. Improvements in the treatment of aggression will increasingly allow affected individuals to benefit from behavioral and educational interventions, thus improving the quality of life for those afflicted with these serious disorders.

Drug names: carbamazepine (Tegretol, Epitol, and others), citalopram (Clecka), clomipramine (Anafranil and others), clonidine (Catapres and others), clonazepam (Clonazepam and others), desipramine (Norpramin and others), divalproex sodium (Depakote), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), guanfacine (Tenex and others), haloperidol (Haldol and others), lamotrigine (Lamictal), methylphenidate (Ritalin, Concerta, and others), mirtazapine (Remeron), molindone (Moban), nadolol (Corgard and others), olanzapine (Zyprexa), paroxetine (Paxil), propranolol (Inderal and others), quetiapine (Seroquel), risperidone (Risperdal), sertraline (Zoloft), thiouracil (Mellilari and others), trazodone (Desyrel and others), ziprasidone (Geodon).

Disclosure of off-label usage: The authors of this article have determined that, to the best of their knowledge, carbamazepine, citalopram, molindone, and thioridazine are not approved by the U.S. Food and Drug Administration for the treatment of conduct disorder; clomipramine, clonazepam, desipramine, fluvoxamine, guanfacine, lamotrigine, mirtazapine, nadolol, olanzapine, quetiapine, sertraline, and zonisamide are not approved for the treatment of autistic disorder; clonidine, haloperidol, lithium, methylphenidate, paroxetine, propranolol, and risperidone are not approved for the treatment of autistic disorder and conduct disorder; divalproex sodium is not approved for the treatment of pervasive developmental disorder, conduct disorder, and oppositional defiant disorder; fluoxetine is not approved for the treatment of pervasive developmental disorder; and trazodone is not approved for the treatment of disruptive behavior disorder.

REFERENCES
2. Posey DJ, McDougle CJ. The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders. Harv Rev Psychiatry 2000;8:45–63
64. Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr 2000;39:15–25